Collabio Spaces by XCDS at Web Summit 2020: Discover the Benefits of Team Collaboration
Shaping the future of teamwork is a difficult challenge and Collabio® Spaces by XCDS is ready to take it head on. After several years of stealth mode development, the team which includes former QuickOffice™ engineers released their alternative view on collaboration around documents and co-authoring. Their software works with the majority of popular office document formats and enables real time collaboration even without Internet connection and clouds. Collabio Spaces allows you to share access to your documents whilst keeping them exceptionally and solely on your private mobile or desktop device.
The next step in the app's evolution is taking part in Web Summit — the "best technology conference on the planet", according to Forbes. Collabio Spaces team will join 100.000+ attendees, 800+ speakers and 2500+ startups on December 2-4, 2020.
The team will speak about technologies behind cloudless collaboration and real time co-authoring, present our product and meet with partners.
"We'll join Web Summit to share our ideas and get feedback from the most innovative community in our world. This is the place where the future is shaped and we'd like to place our stake in this process," said Andy Webb, CEO.
At Web Summit, the Collabio Spaces team will hold two roundtables:
-
"Co-authoring documents. What’s good and what’s still missing" —15:00 - 15:45 (UK Time) on Wednesday, December 2, 2020.
You'll learn how to improve your teamwork on documents and why you should pay attention to that, we will speak of which document co-editing issues are left to be resolved and how they may be fixed. Also, you'll get a bunch of useful tips for effective co-authoring, which will boost your team's productivity!
If you write or review documents, lead teams of authors and aim to achieve results at tough deadlines or want to raise the quality of final documents, we expect this roundtable will be valuable for you!
-
"Under the hood of cloudless collaboration" — 14:00 - 15:45 (UK Time) on Thursday, December 3, 2020.
Collabio Spaces' tech team will share their hands-on experience on enabling team collaboration in a simple WiFi network. You will find out how to make an iPhone the nexus point of documents co-editing without involving any external servers. We'll discuss the magic behind this cloudless technology and the model that we fitted into the tough requirements of mobile device computing power!
Are you a tech geek or just take interest in peer-to-peer technologies and mobile applications? We're waiting for you at this roundtable!
To learn more about the App and our plans for Web Summit 2020, visit the official website and feel free to ask us any questions on socials or via email.
XCDS is a software development company that creates user-friendly and efficient office software for iOS, macOS, Windows and Linux devices, and now — our new innovative and convenient iOS app.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201130005090/en/
Contact information
Press Contact
Valentina Podmazina
valentina.podmazina@collabio.team
+44 745 128 5022
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom